All In Biotech

Drug Trial Radar · NCT06559007

Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants

A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Dose HRS-5041 in Healthy Caucasian Male Participants

Last checked: Nov 20, 2026Latest source record: Mar 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Sep 25, 2024

Primary completion

Jan 6, 2025

Study completion Mar 3, 2025

Sponsor

Lead sponsor
Atridia Pty Ltd.Industry
Sponsor type
Industry
First posted
Aug 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase 1, open-label, randomized study. The objective of this study is to evaluate the PK, safety and tolerability of orally administered single-dose HRS-5041 in healthy Caucasian male participants.

Conditions

  • Prostate Cancer

Interventions

  • HRS-5041 dose level 1Drug

    Single dose of HRS-5041 orally administered

  • HRS-5041 dose level 2Drug

    Single dose of HRS-5041 orally administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK profile (Cmax) of HRS-5041 after a single oral (PO) administration:Time frame: Day 10
  2. PK profile (AUC0-t) of HRS-5041 after a single oral (PO) administration:Time frame: Day 10
  3. PK profile (AUC0-inf) of HRS-5041 after a single oral (PO) administration:Time frame: Day 10
  4. PK profile (Tmax) of HRS-5041 after a single oral (PO) administration:Time frame: Day 10
  5. PK profile ( t1/2) of HRS-5041 after a single oral (PO) administration:Time frame: Day 10
  6. PK profile (CL/F) of HRS-5041 after a single oral (PO) administration:Time frame: Day 10
  7. PK profile (Vz/F) of HRS-5041 after a single oral (PO) administration:Time frame: Day 10

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Melbourne

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.